A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)
- 1 August 2006
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 45 (2) , 204-213
- https://doi.org/10.1016/j.jhep.2006.03.008
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Pegylating IFNs at His-34 Improves the in Vitro Antiviral Activity Through the JAK/STAT PathwayAntiviral Chemistry and Chemotherapy, 2004
- Of JAKs, STATs, blind watchmakers, jeeps and trainsFEBS Letters, 2003
- Structural and Biologic Characterization of Pegylated Recombinant IFN-α2bJournal of Interferon & Cytokine Research, 2001
- Antiviral Actions of InterferonsClinical Microbiology Reviews, 2001
- Estimating future hepatitis C morbidity, mortality, and costs in the United StatesAmerican Journal of Public Health, 2000
- Identification of the Major Positional Isomer of Pegylated Interferon Alpha-2bBiochemistry, 2000
- Rising Incidence of Hepatocellular Carcinoma in the United StatesNew England Journal of Medicine, 1999
- Positional Isomers of Monopegylated Interferon α-2a: Isolation, Characterization, and Biological ActivityAnalytical Biochemistry, 1997
- An Overview of the Interferon System: Signal Transduction and Mechanisms of ActionCancer Investigation, 1996
- Biomedical and biotechnological applications of PEG- and PM-modified proteinsTrends in Biotechnology, 1995